Although CD8α and CD28 spacers have been extensively utilized in numerous clinical anti-CD19-CAR trials demonstrating potent anti-tumor efficacy [14,19,20,89], the impact of these hinges on CAR T cell performance has not been thoroughly investigated as of yet, thus their use remains largely empirical. The gene discussed is CD8A; the disease is neoplasm.